Pulmatrix Inc

NASDAQ PULM

Data sourced from iex and EODHD
Download Data

Pulmatrix Inc Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2024: 12.69%

Pulmatrix Inc Pre-Tax Margin is 12.69% for the Trailing 12 Months (TTM) ending March 31, 2024, a 104.32% change year over year. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.
  • Pulmatrix Inc Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -293.51%, a 25.79% change year over year.
  • Pulmatrix Inc Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -395.54%, a -469.38% change year over year.
  • Pulmatrix Inc Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -69.47%, a 59.88% change year over year.
  • Pulmatrix Inc Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2020 was -173.15%, a 94.93% change year over year.
NASDAQ: PULM

Pulmatrix Inc

CEO Mr. Teofilo David Raad MBA
IPO Date March 21, 2014
Location United States
Headquarters 99 Hayden Avenue, Lexington, MA, United States, 02421
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

StockViz Staff

September 20, 2024

Any question? Send us an email